PD Neurogenesis and Neuroregeneration Companies

Parkinson's Disease Neurogenesis and Neuroregeneration Companies

Overview

This page catalogs biotechnology and pharmaceutical companies developing therapies that promote neurogenesis, neuroregeneration, or cell replacement for Parkinson's disease (PD). These approaches aim to restore dopaminergic neurons, repair damaged neural circuits, or enhance the brain's natural regenerative capacity — representing a paradigm shift from symptom management toward disease modification and potential cure.

Key Approaches

Parkinson's Disease Neurogenesis and Neuroregeneration Companies

Overview

This page catalogs biotechnology and pharmaceutical companies developing therapies that promote neurogenesis, neuroregeneration, or cell replacement for Parkinson's disease (PD). These approaches aim to restore dopaminergic neurons, repair damaged neural circuits, or enhance the brain's natural regenerative capacity — representing a paradigm shift from symptom management toward disease modification and potential cure.

Key Approaches

| Approach | Description | Companies |
|----------|-------------|-----------|
| Cell Replacement | Transplanting dopamine-producing neurons derived from stem cells | BlueRock, Aspen, Cellino, Renascience, Sumitomo |
| Neurotrophic Factors | Delivering GDNF, BDNF, or HGF to support neuron survival | PharmaEssentia, Athira, BrainStorm |
| Mitochondrial Restoration | Repairing energy metabolism in dopaminergic neurons | Cytochrome Therapeutics, Vandria |
| Endogenous Regeneration | Activating brain's own repair mechanisms | Multiple small molecule programs |

Cell Replacement Therapies

BlueRock Therapeutics

Status: Phase III (exPDite-2) enrolling

BlueRock's lead program [bemdaneprocel (BRII-001)](https://www.bluerocktx.com/) is an off-the-shelf dopamine neuron replacement therapy using human embryonic stem cell (hESC)-derived dopaminergic progenitor cells. The Phase I trial (NCT04802733) completed in 12 patients with advanced PD, showing promising results at 18-24 month follow-up with 21.9-point UPDRS-III improvement in high-dose cohort[@tabar2025][@kirkeby2024]. Now advancing to registrational Phase III (exPDite-2, NCT05887418) with ~102 patients expected to complete in 2027-2028.

• Cell Source: hESC-derived dopaminergic progenitors
• Delivery: Bilateral putamenal transplantation
• Immunosuppression: Required for 12 months post-transplant

Aspen Neuroscience

Status: Phase 1/2 (dRIP Trial recruiting)

Aspen Neuroscience is developing autologous iPSC-derived dopamine neurons:

| Program | Description | Stage |
|---------|-------------|-------|
| ANPD001 | Autologous iPSC-derived dopamine neurons | Phase 1/2 (dRIP Trial) |
| ANPD002 | Allogeneic iPSC-derived dopamine neurons | Preclinical |

[ASPEN Neuroscience](/companies/aspen-neuroscience)

Cellino Biotech

Status: Preclinical

Cellino is developing [CLNO-001](/companies/cellino-biotech), an autologous iPSC-derived dopamine neuron therapy using patient-derived cells to minimize immune rejection.

[Cellino Biotech](/companies/cellino-biotech)

Renascience Inc.

Status: Preclinical (RS-001)

Tokyo-based Renascience is developing [RS-001](/companies/renascience), an iPSC-derived dopaminergic neuron transplantation therapy for PD.

[Renascience](/companies/renascience)

Sumitomo Pharma

Status: Research (CTI-ND1601)

Sumitomo Pharma (formerly Sumitomo Dainippon Pharma) has a Japanese partnership developing [CTI-ND1601](/companies/sumitomo-pharma), iPSC-derived dopaminergic neuron progenitor cells for Parkinson's disease[@parmar2024].

[Sumitomo Pharma](/companies/sumitomo-pharma)

Neurotrophic Factor Therapies

PharmaEssentia

Status: Research

PharmaEssentia is developing [PE-003](/companies/pharmaessentia), a neurotrophic factor program targeting:

• GDNF delivery: PEGylated glial cell line-derived neurotrophic factor variants
• BDNF therapeutics: PEGylated brain-derived neurotrophic factor

[PharmaEssentia](/companies/pharmaessentia)

Athira Pharma

Status: Phase 2 (AD), Planning (PD)

Athira Pharma's lead program [fosgonimeton (ATH-1017)](https://www.athirapharma.com) is a small molecule HGF/MET activator that promotes:

• Neuronal survival and protection
• Synaptic function and plasticity
• Neurogenesis
• [Neuroinflammation](/mechanisms/neuroinflammation) modulation

[Athira Pharma](/companies/athira-pharma)

BrainStorm Cell Therapeutics

Status: Phase 1/2

BrainStorm's [NurOwn](/companies/brainstorm-cell-therapeutics) is an autologous mesenchymal stem cell (MSC) therapy that secretes neurotrophic factors (MSC-NTF). While primarily developed for ALS, the neurotrophic factor secretion mechanism is relevant to PD.

[BrainStorm Cell Therapeutics](/companies/brainstorm-cell-therapeutics)

Mitochondrial Restoration

Cytochrome Therapeutics

Status: Phase 1b active

Cytochrome Therapeutics is developing [CT-101](/companies/cytochrome-therapeutics), a first-in-class small molecule mitochondrial Complex I restorer targeting the fundamental bioenergetic defect underlying dopaminergic neuron degeneration in PD.

[Cytochrome Therapeutics](/companies/cytochrome-therapeutics)

Vandria

Status: Research

Vandria is developing mitochondrial restoration approaches, including [NRG-001](/companies/vandria), targeting energy restoration in neurons with impaired respiratory chain function.

[Vandria](/companies/vandria)

Pipeline Overview

| Company | Program | Mechanism | Indication | Stage |
|---------|---------|-----------|------------|-------|
| BlueRock | Bemdaneprocel | hESC dopamine neurons | PD | Phase I complete |
| Aspen | ANPD001 | Autologous iPSC neurons | PD | Phase 1/2 |
| Cellino | CLNO-001 | Autologous iPSC neurons | PD | Preclinical |
| Renascience | RS-001 | iPSC dopamine neurons | PD | Preclinical |
| Sumitomo | CTI-ND1601 | iPSC dopamine neurons | PD | Research |
| PharmaEssentia | PE-003 | Neurotrophic factors | PD | Research |
| Athira | Fosgonimeton | HGF/MET activator | PD (planned) | Phase 2 |
| BrainStorm | NurOwn | MSC-NTF | PD | Phase 1/2 |
| Cytochrome | CT-101 | Complex I restorer | PD | Phase 1b |
| Vandria | NRG-001 | Mitochondrial restoration | PD | Research |

Scientific Background

Dopamine Neuron Replacement

Parkinson's disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Cell replacement approaches aim to replace these lost neurons with new dopamine-producing cells that can restore motor function[@parmar2024].

Key requirements for successful cell therapy:

• Proper dopaminergic neuron specification (A9 subtype)
• Appropriate migration and integration into host circuitry
• Long-term survival without tumor formation
• Ethical cell source considerations (hESC vs. iPSC vs. fetal tissue)

Neurotrophic Factor Support

Neurotrophic factors like GDNF and BDNF promote neuron survival and can enhance the effectiveness of cell replacement therapies[@singh2016]. However, delivery to the brain remains challenging due to the blood-brain barrier.

Clinical Trial Landscape

• Active PD cell therapy trials: ~5 (2025-2026)
• Key endpoints: Motor scores (UPDRS), PET imaging of dopamine function, dyskinesia assessment
• Challenges: Immunosuppression requirements, cell dosing, surgical delivery

Cross-References

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Parkinson's Disease Pipeline Companies](/companies/pd-pipeline-companies)
• [Induced Pluripotent Stem Cells](/technologies/ipsc-technology)
• [Gene Therapy](/technologies/gene-therapy)
• [Neurotrophic Factors](/mechanisms/neurotrophic-factors)
• [Neuroregeneration Pathway](/mechanisms/neuroregeneration-pathway)
• [Cell Therapy Technologies](/technologies/cell-therapy)

External Links

• [ClinicalTrials.gov - Parkinson's Cell Therapy](https://clinicaltrials.gov/search?cond=Parkinson%27s+disease&intr=cell+therapy)
• [Michael J. Fox Foundation - Parkinson's Progress](https://www.michaeljfox.org/parkinsons-progress)

Pathway Diagram

The following diagram shows the key molecular relationships involving PD Neurogenesis and Neuroregeneration Companies discovered through SciDEX knowledge graph analysis: